Cardiol Therapeutics (CRDL) Price & Analysis

Compare

197 Followers

CRDL Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$1.09 - C$3.28

Previous CloseN/A

Volume34.34K

Average Volume (3M)174.66K

Market Cap

$125.59M

Enterprise ValueC$134.86M

Total Cash (Recent Filing)$18.20M

Total Debt (Recent Filing)$142.55K

Price to Earnings (P/E)―

Beta1.90

Next Earnings

Nov 18, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding83,729,450

10 Day Avg. Volume94,894

30 Day Avg. Volume174,660

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.07

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.29K

Enterprise Value/Ebitda-3.38

Forecast

1Y Price Target

$12.13

Price Target Upside682.42% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical SafetyCardiolRx was well-tolerated with no new safety signals observed, enhancing its attractiveness.

Efficacy Of CardiolRxThe ARCHER study results bring important, additional proof-of-concept data on the anti-inflammatory effect of CardiolRx in a second indication.

Market ValuationCRDL's current market cap does not reflect the positive outcomes of the ARCHER trial, suggesting an undervaluation of the stock.

Bears Say

Primary Endpoint ResultsWhile CardiolRx showed a 'notable improvement' in extracellular volume (ECV) one of the two primary endpoints, the measure was NOT statistically significant at p=0.0538.

Trial Endpoint ChallengesNo significant difference was observed in the second primary endpoint of global longitudinal strain (GLS).

Cardiol Therapeutics News

Cardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Cardiol Therapeutics and keeping the price target...

1M ago

CRDL

Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses

Cardiol Therapeutics ( ($TSE:CRDL) ) has issued an update. Cardiol Therapeutics Inc. released its financial results for the...

1M ago

CRDL

Cardiol Therapeutics to Present at Canaccord Genuity Conference

Cardiol Therapeutics ( ($TSE:CRDL) ) has shared an announcement. Cardiol Therapeutics announced its participation in a Fireside Chat...

1M ago

CRDL

Roth bullish on Cardiol, says trial results enough to attract larger partner

Keeping a Buy rating on Cardiol Therapeutics (CRDL), Roth Capital notes that top-line results for the ARCHER for...

2M ago

CRDL

Optimistic Buy Rating for Cardiol Therapeutics Amid Promising Clinical Trial Results and Strategic Advancements

Cardiol Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward Nash from...

2M ago

CRDL

Cardiol ARCHER study not statistically significant, says Canaccord

Canaccord says that while the top-line results from Cardiol Therapeutics (CRDL)’ Phase II ARCHER trial in patients with...

2M ago

CRDL

Cardiol falls 14% to $1.16 after myocarditis study results

10:08 EDT Cardiol falls 14% to $1.16 after myocarditis study results Published first on TheFly – the ultimate...

2M ago

CRDL

Cardiol data readout positive and not priced in, says H.C. Wainwright

H.C. Wainwright views the results from ardiol Therapeutics’ Phase II ARCHER trial of CardiolRx in acute myocarditis as...

2M ago

CRDL

Cardiol Therapeutics announces Phase II ARCHER results in myocarditis

Cardiol Therapeutics (CRDL) announced topline results from ARCHER, the company’s Phase II clinical trial in patients with acute...

2M ago

CRDL

Cardiol Therapeutics Reports Promising Phase II Trial Results for CardiolRx™ in Acute Myocarditis

An update from Cardiol Therapeutics ( ($TSE:CRDL) ) is now available. Cardiol Therapeutics announced positive topline results from...

2M ago

CRDL

Positive Outlook for Cardiol Therapeutics Amid ARCHER Trial Progress and Market Potential

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Cardiol Therapeutics today and set a price target...

2M ago

CRDL

Cardiol Therapeutics Achieves Database Lock in ARCHER Trial for Acute Myocarditis

Cardiol Therapeutics ( ($TSE:CRDL) ) has issued an update. On July 22, 2025, Cardiol Therapeutics announced the database...

2M ago

CRDL

Buy Rating for Cardiol Therapeutics: Promising Innovations in Heart Disease Treatment with CardiolRx and CRD-38

Brandon Folkes, an analyst from Rodman & Renshaw, has initiated a new Buy rating on Cardiol Therapeutics (CRDL)....

4M ago

CRDL

Cardiol Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $9 price target Cardiol is...

4M ago

CRDL

CRDL FAQ

What was Cardiol Therapeutics’s price range in the past 12 months?

Cardiol Therapeutics lowest stock price was C$1.09 and its highest was C$3.28 in the past 12 months.

What is Cardiol Therapeutics’s market cap?

Cardiol Therapeutics’s market cap is $125.59M.

When is Cardiol Therapeutics’s upcoming earnings report date?

Cardiol Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 59 days.

How were Cardiol Therapeutics’s earnings last quarter?

Cardiol Therapeutics released its earnings results on Aug 14, 2025. The company reported -C$0.1 earnings per share for the quarter, beating the consensus estimate of -C$0.123 by C$0.023.

Is Cardiol Therapeutics overvalued?

According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cardiol Therapeutics pay dividends?

Cardiol Therapeutics does not currently pay dividends.

What is Cardiol Therapeutics’s EPS estimate?

Cardiol Therapeutics’s EPS estimate is -0.11.

How many shares outstanding does Cardiol Therapeutics have?

Cardiol Therapeutics has 83,729,450 shares outstanding.

What happened to Cardiol Therapeutics’s price movement after its last earnings report?

Cardiol Therapeutics reported an EPS of -C$0.1 in its last earnings report, beating expectations of -C$0.123. Following the earnings report the stock price went down -1.081%.

Which hedge fund is a major shareholder of Cardiol Therapeutics?

Currently, no hedge funds are holding shares in TSE:CRDL

Cardiol Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-271.56%

Trailing 12-Months

Asset Growth

-24.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cardiol Therapeutics

Cardiol Therapeutics (CRDL) is a clinical-stage biotechnology company focused on the research and development of innovative anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases. The company operates primarily in the biopharmaceutical sector and is dedicated to advancing its proprietary cannabidiol-based formulations for heart failure and acute myocarditis, aiming to address unmet medical needs in these areas.

Cardiol Therapeutics (CRDL) Earnings & Revenues

Historic Earnings Reports

CRDL Stock 12 Month Forecast

Average Price Target

C$12.13

▲(682.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","4":"C$4","8":"C$8","12":"C$12","16":"C$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.15932451,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$15.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.127459608,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$12.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.26872246,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$8.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.52,2.5691788084615386,3.618357616923077,4.667536425384616,5.716715233846154,6.765894042307693,7.815072850769232,8.864251659230769,9.913430467692308,10.962609276153847,12.011788084615386,13.060966893076923,14.110145701538462,{"y":15.15932451,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.52,2.3359584313846153,3.151916862769231,3.9678752941538464,4.783833725538462,5.599792156923078,6.415750588307693,7.231709019692309,8.047667451076924,8.86362588246154,9.679584313846155,10.49554274523077,11.311501176615385,{"y":12.127459608,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.52,2.039132496923077,2.558264993846154,3.077397490769231,3.596529987692308,4.115662484615385,4.634794981538462,5.153927478461538,5.673059975384616,6.192192472307692,6.71132496923077,7.230457466153846,7.749589963076923,{"y":8.26872246,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.57,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.605,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.695,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >